search
for
 About Bioline  All Journals  Testimonials  Membership  News  Donations


Memórias do Instituto Oswaldo Cruz
Fundação Oswaldo Cruz, Fiocruz
ISSN: 1678-8060
EISSN: 1678-8060
Vol. 102, No. 3, 2007, pp. 313-317
Bioline Code: oc07053
Full paper language: English
Document type: Research Article
Document available free of charge

Memórias do Instituto Oswaldo Cruz, Vol. 102, No. 3, 2007, pp. 313-317

 en Adjuvant requirement for successful immunization with recombinant derivatives of Plasmodium vivax check for this species in other resources merozoite surface protein-1 delivered via the intranasal route
Bargieri, Daniel Y; Rosa, Daniela S; Lasaro, Melissa Ang Simões; Ferreira, Luis Carlos S; Soares, Irene S & Rodrigues, Mauricio M

Abstract

Recently, we generated two bacterial recombinant proteins expressing 89 amino acids of the C-terminal domain of the Plasmodium vivax merozoite surface protein-1 and the hexa-histidine tag (His6MSP119). One of these recombinant proteins contained also the amino acid sequence of the universal pan allelic T-cell epitope (His6MSP119-PADRE). In the present study, we evaluated the immunogenic properties of these antigens when administered via the intra-nasal route in the presence of distinct adjuvant formulations. We found that C57BL/6 mice immunized with either recombinant proteins in the presence of the adjuvants cholera toxin (CT) or the Escherichia coli heat labile toxin (LT) developed high and long lasting titers of specific serum antibodies. The induced immune responses reached maximum levels after three immunizing doses with a prevailing IgG1 subclass response. In contrast, mice immunized by intranasal route with His6MSP119-PADRE in the presence of the synthetic oligonucleotides adjuvant CpG ODN 1826 developed lower antibody titers but when combined to CT, CpG addition resulted in enhanced IgG responses characterized by lower IgG1 levels. Considering the limitations of antigens formulations that can be used in humans, mucosal adjuvants can be a reliable alternative for the development of new strategies of immunization using recombinant proteins of P. vivax.

Keywords
Plasmodium vivax - mucosal immunization - recombinant vaccines - adjuvants

 
© Copyright 2007 Instituto Oswaldo Cruz - Fiocruz
Alternative site location: http://memorias.ioc.fiocruz.br

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2017, Site last up-dated on 16-Oct-2017.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil